EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sorrento Therapeutics's enterprise value is $129.23 Mil.
Sorrento Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-532.12 Mil. Therefore, Sorrento Therapeutics's EV-to-EBITDA for today is -0.24.
The historical rank and industry rank for Sorrento Therapeutics's EV-to-EBITDA or its related term are showing as below:
SRNE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.25 Med: 0 Max: 0
Current: -0.24
SRNE's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 7.19
vs SRNE: -0.24
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Sorrento Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Sorrento Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sorrento Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Sorrento Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sorrento Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sorrento Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sorrento Therapeutics's EV-to-EBITDA falls into.
Sorrento Therapeutics's current Enterprise Value is $129.23 Mil.
Sorrento Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-532.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sorrento Therapeutics's PE Ratio (TTM) for today is calculated as:
Sorrento Therapeutics's share price for today is $0.001.
Sorrento Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.120.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Sorrento Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SRNE has been successfully added to your 